ASTRAZENECA and Oxford University’s coronavirus vaccine is 100 per cent effective against severe disease, a US study has shown.
The jab was also found to be 79 per cent effective at preventing symptomatic illness – paving the way for approval in the US.
Read our coronavirus live blog for the latest news & updates…
The fresh data comes after a string of European countries resumed use of the vaccine following unsubstantiated blood clot fears.
AstraZeneca today said an independent safety committee conducted a specific review of the blood clots in the US trial, and found “no increased risk of thrombosis”.
More than 32,000 people across all age groups took part in the trial in the US as well as Chile and Peru.
Andrew Pollard, who runs the Oxford Vaccine Group, said: “These results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results from Oxford-led trials.
“We can expect strong impact against Covid-19 across all ages and for people of all different backgrounds from widespread use of the vaccine.”
